
MTVA Stock Forecast & Price Target
MTVA Analyst Ratings
Bulls say
MetaVia Inc. is demonstrating promising clinical results with its leading candidate, DA-1726, a novel dual agonist for obesity, which has shown an average reduction in fasting glucose levels of 5.3 mg/dL, with some cases reaching reductions as high as 18 mg/dL within just two days. Additionally, the treatment has led to a significant reduction in waist circumference, averaging 1.6 inches from a baseline of 41 inches, and achieving a maximum decrease of 3.9 inches by Day 33. Importantly, DA-1726 has shown a maximum body weight loss of 6.3% from baseline with a mean loss of 4.3% at Day 26, indicating sustained efficacy without signs of plateauing, which could enhance MetaVia's market potential for treating cardiometabolic diseases.
Bears say
MetaVia Inc faces several significant risks impacting its investment outlook, primarily stemming from ongoing clinical trials and commercial viability. The negative sentiment is underscored by disappointing results from the Phase 1 study of DA-1726 for obesity and challenges in establishing a combination therapy for DA-1241 in metabolic dysfunction-associated steatohepatitis (MASH). Additionally, potential delays in development timelines, smaller than expected market opportunities due to competition and pricing, along with funding constraints, further exacerbate concerns surrounding the company's future prospects.
This aggregate rating is based on analysts' research of NeuroBo Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MTVA Analyst Forecast & Price Prediction
Start investing in MTVA
Order type
Buy in
Order amount
Est. shares
0 shares